Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Finished Goods (2017 - 2019)

Historic Finished Goods for Ironwood Pharmaceuticals (IRWD) over the last 3 years, with Q4 2019 value amounting to $191000.0.

  • Ironwood Pharmaceuticals' Finished Goods changed N/A to $191000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $191000.0, marking a year-over-year change of. This contributed to the annual value of $191000.0 for FY2019, which is N/A changed from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Finished Goods stood at $191000.0 for Q4 2019.
  • Over the past 5 years, Ironwood Pharmaceuticals' Finished Goods peaked at $1.4 million during Q1 2018, and registered a low of $76000.0 during Q3 2018.
  • Its 3-year average for Finished Goods is $589428.6, with a median of $479000.0 in 2017.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Finished Goods crashed by 8413.36% in 2018, and later soared by 50131.58% in 2019.
  • Ironwood Pharmaceuticals' Finished Goods (Quarter) stood at $735000.0 in 2017, then tumbled by 89.66% to $76000.0 in 2018, then surged by 151.32% to $191000.0 in 2019.
  • Its Finished Goods was $191000.0 in Q4 2019, compared to $457000.0 in Q3 2019 and $76000.0 in Q3 2018.